Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 2
1969 1
1971 1
1972 2
1973 1
1974 1
1975 1
1976 1
1978 4
1979 4
1980 3
1982 1
1984 1
1985 2
1987 2
1988 1
1989 2
1991 2
1992 2
1993 2
1994 4
1995 3
1996 6
1997 2
1998 5
1999 3
2000 2
2001 3
2002 2
2003 6
2004 7
2005 13
2006 5
2007 10
2008 4
2009 13
2010 19
2011 23
2012 22
2013 24
2014 25
2015 23
2016 29
2017 23
2018 51
2019 57
2020 45
2021 41
2022 41
2023 43
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

545 results

Results by year

Filters applied: . Clear all
Page 1
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP; RAPIDO collaborative investigators. Bahadoer RR, et al. Among authors: cervantes a. Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7. Lancet Oncol. 2021. PMID: 33301740 Clinical Trial.
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.
Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund Å, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B; Collaborative Investigators. Dijkstra EA, et al. Among authors: cervantes a. Ann Surg. 2023 Oct 1;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799. Epub 2023 Jan 20. Ann Surg. 2023. PMID: 36661037 Free PMC article. Clinical Trial.
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cervantes A, et al. Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25. Ann Oncol. 2023. PMID: 36307056 Free article. No abstract available.
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.
Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice MG, Luise C, Erreni M, Pece S, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Bertocchi A, et al. Among authors: cervantes a. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: 10.1016/j.ccell.2021.03.004. Epub 2021 Apr 1. Cancer Cell. 2021. PMID: 33798472 Free article.
Integration of oncology and palliative care: a Lancet Oncology Commission.
Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E, Brunelli C, Caraceni A, Cervantes A, Currow DC, Deliens L, Fallon M, Gómez-Batiste X, Grotmol KS, Hannon B, Haugen DF, Higginson IJ, Hjermstad MJ, Hui D, Jordan K, Kurita GP, Larkin PJ, Miccinesi G, Nauck F, Pribakovic R, Rodin G, Sjøgren P, Stone P, Zimmermann C, Lundeby T. Kaasa S, et al. Among authors: cervantes a. Lancet Oncol. 2018 Nov;19(11):e588-e653. doi: 10.1016/S1470-2045(18)30415-7. Epub 2018 Oct 18. Lancet Oncol. 2018. PMID: 30344075 Free article. Review.
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Obermannová R, et al. Among authors: cervantes a. Ann Oncol. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. Epub 2022 Jul 29. Ann Oncol. 2022. PMID: 35914638 Free article. No abstract available.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. Among authors: cervantes a. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Glioma epileptiform activity and progression are driven by IGSF3-mediated potassium dysregulation.
Curry RN, Aiba I, Meyer J, Lozzi B, Ko Y, McDonald MF, Rosenbaum A, Cervantes A, Huang-Hobbs E, Cocito C, Greenfield JP, Jalali A, Gavvala J, Mohila C, Serin Harmanci A, Noebels J, Rao G, Deneen B. Curry RN, et al. Among authors: cervantes a. Neuron. 2023 Mar 1;111(5):682-695.e9. doi: 10.1016/j.neuron.2023.01.013. Epub 2023 Feb 13. Neuron. 2023. PMID: 36787748 Free PMC article.
545 results